BNP Paribas Financial Markets
CRNX icon

BNP Paribas Financial Markets’s Crinetics Pharmaceuticals CRNX Stock Holding History

BNP Paribas Financial Markets’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Buy
45,334
+65
+0.1% +$2.42K ﹤0.01% 2934
2026
Q1 		$1.64M Buy
45,269
+17,736
+64% +$792K ﹤0.01% 2792
2025
Q4 		$1.28M Buy
27,533
+3,566
+15% +$159K ﹤0.01% 2931
2025
Q3 		$998K Buy
23,967
+8,212
+52% +$263K ﹤0.01% 3136
2025
Q2 		$453K Buy
15,755
+5,287
+51% +$163K ﹤0.01% 3383
2025
Q1 		$351K Sell
10,468
-4,791
-31% -$179K ﹤0.01% 3379
2024
Q4 		$780K Sell
15,259
-5,683
-27% -$318K ﹤0.01% 2989
2024
Q3 		$1.07M Buy
20,942
+12,000
+134% +$619K ﹤0.01% 2455
2024
Q2 		$401K Sell
8,942
-37,018
-81% -$1.71M ﹤0.01% 2778
2024
Q1 		$2.15M Sell
45,960
-134,535
-75% -$5.26M ﹤0.01% 2010
2023
Q4 		$6.42M Sell
180,495
-123,625
-41% -$3.79M 0.01% 1264
2023
Q3 		$9.04M Buy
304,120
+244,960
+414% +$5.05M 0.01% 945
2023
Q2 		$1.07M Buy
59,160
+372
+0.6% +$7.42K ﹤0.01% 2158
2023
Q1 		$944K Buy
58,788
+31,144
+113% +$576K ﹤0.01% 2355
2022
Q4 		$506K Sell
27,644
-17,841
-39% -$314K ﹤0.01% 2569
2022
Q3 		$893K Buy
45,485
+33,443
+278% +$682K ﹤0.01% 2577
2022
Q2 		$225K Buy
12,042
+8,119
+207% +$162K ﹤0.01% 3033
2022
Q1 		$86.1K Sell
3,923
-6,561
-63% -$133K ﹤0.01% 3401
2021
Q4 		$298K Buy
10,484
+3,625
+53% +$89.4K ﹤0.01% 3249
2021
Q3 		$144K Buy
6,859
+5,387
+366% +$113K ﹤0.01% 3154
2021
Q2 		$27.7K Sell
1,472
-2,169
-60% -$38.1K ﹤0.01% 3453
2021
Q1 		$55.6K Sell
3,641
-2,776
-43% -$43K ﹤0.01% 3583
2020
Q4 		$90.5K Sell
6,417
-163
-2% -$2.27K ﹤0.01% 3261
2020
Q3 		$103K Buy
6,580
+5,064
+334% +$77.4K ﹤0.01% 3097
2020
Q2 		$26.6K Sell
1,516
-1,931
-56% -$32.9K ﹤0.01% 3272
2020
Q1 		$50.7K Buy
3,447
+1,823
+112% +$37.4K ﹤0.01% 3532
2019
Q4 		$40.7K Buy
1,624
+56
+4% +$1.07K ﹤0.01% 3747
2019
Q3 		$23.6K Buy
1,568
+546
+53% +$10.6K ﹤0.01% 3879
2019
Q2 		$25.6K Sell
1,022
-826
-45% -$20.5K ﹤0.01% 3806
2019
Q1 		$42.1K Buy
+1,848
New +$45.4K ﹤0.01% 3603

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BNP Paribas Financial Markets's CRNX Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Crinetics Pharmaceuticals (CRNX) stake by 0.14% in Q2 2026, buying an estimated $2.42K and bringing the position to 45,334 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2934.

BNP Paribas Financial Markets first reported a position in CRNX in Q1 2019 and has held it in 30 quarters since. The position peaked at $9.04M in Q3 2023. 250 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • BNP Paribas Financial Markets held 45,334 shares of Crinetics Pharmaceuticals worth $1.7M as of Q2 2026.
  • BNP Paribas Financial Markets bought 65 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $2.42K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2934 holding.
  • BNP Paribas Financial Markets first reported a position in Crinetics Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
  • BNP Paribas Financial Markets's Crinetics Pharmaceuticals position peaked at $9.04M in Q3 2023.
  • 250 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.